PreludeDx Announces New Response Type Biosignature Data at the 37th Annual Miami Breast Cancer Conference
New Response Type Biosignature Identifies Women at Elevated Risk of Recurrence after Surgery and Radiation Therapy for DCIS
DCISionRT integration into decision-making changed treatment recommendations in 45% of women with DCIS
Prospective Trial near... Diagnostics, Oncology PreludeDx, DCISionRT, ductal carcinoma, breast cancer, DCIS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 6, 2020 Category: Pharmaceuticals Source Type: news
Neoadjuvant Imatinib for an Uncommon Breast Malignancy Neoadjuvant Imatinib for an Uncommon Breast Malignancy
This case highlights the differentiation of dermatofibrosarcoma protuberans from metaplastic breast carcinoma and other spindle cell lesions, as well as the use of imatinib as neoadjuvant treatment.Journal of Medical Case Reports (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 18, 2020 Category: Surgery Tags: Family Medicine/Primary Care Journal Article Source Type: news
China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy available in China...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news
China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy available in China...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news
Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer
Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Data from 194 Chinese patients who took part in the IMbrave150 study were consistent with the global results, that showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survi...
Source: Roche Investor Update - February 7, 2020 Category: Pharmaceuticals Source Type: news
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient...
Source: Roche Investor Update - January 27, 2020 Category: Pharmaceuticals Source Type: news
RT for DCIS Ups Mortality Risk in Invasive Second Breast Cancer
FRIDAY, Dec. 20, 2019 -- For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently develop an invasive second breast... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2019 Category: Pharmaceuticals Source Type: news
Patients with Invasive Secondary Breast Cancer May Have Higher Mortality
Patients who previously received radiotherapy for ductal carcinoma in situ may have higher mortality after developing an invasive second breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 3, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
New Study Suggests Women With Dense Breast Tissue May Benefit From Regular MRIs
While there has been some controversy over when women should start getting mammograms, all experts agree that screening is an important first step in detecting breast cancers and treating them early. But for some women, that’s not enough. For the approximately 40% of women with dense breast tissue, and especially the 10% with extremely dense tissue, cancer cells are harder to detect, since the denser tissue can mask small growths. In addition, dense breast tissue itself is also a risk factor for developing cancer.
There’s been debate among experts over whether these women should have additional screening, on to...
Source: TIME: Health - November 27, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Breast Cancer embargoed study Research Source Type: news
Mesothelioma Death from 9/11 Signals Start of Things to Come
Malignant mesothelioma has become the latest deadly cancer linked directly to the rescue, recovery and cleanup efforts following the 9/11 terrorist attack on New York City in 2001.
The long-running threat has come to fruition.
Eighteen years after Manhattan was engulfed in the asbestos-laced, toxic cloud of dust — caused primarily by the World Trade Center destruction — the first death from pleural mesothelioma attributed to 9/11 has been recorded.
Nick Ursta, 52, from the southwestern part of Pennsylvania, died after a year-long battle with the rare cancer.
Ursta, a construction worker and fireman by trade, was part ...
Source: Asbestos and Mesothelioma News - November 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma
In a new study, patients with HR+/HER2- early stage breast cancer completed 2 years of adjuvant palbociclib with a similar toxicity profile as that observed in the metastatic setting.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
No Benefit Seen for SLNB in BCS for DCIS in Older Women
THURSDAY, Oct. 31, 2019 -- For older patients with ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery (BCS), sentinel lymph node biopsy (SLNB) is not associated with improvements in long-term outcomes, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2019 Category: Pharmaceuticals Source Type: news
Don't Delay Very Early-Stage Breast Cancer Surgery
Longer delays in surgery for ductal carcinoma in situ (DCIS) breast cancer lead to a higher risk of invasive ductal carcinoma and a slightly lower survival rate, researchers found. (Source: WebMD Health)
Source: WebMD Health - October 25, 2019 Category: Consumer Health News Source Type: news
Delay of Surgery for DCIS Ups Risk for Invasive Breast Cancer
FRIDAY, Oct. 25, 2019 -- For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 25, 2019 Category: Pharmaceuticals Source Type: news
